Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

You searched for:

Home / Exhibit Details Exhibit Details ACCC National Oncology Conference Exhibit Details Conference Date: October 19-21, 2016 Exhibit Hall Schedule & Hours: Wednesday, October 19, 2016 6:00 pm — 7:00 pm President and Exhibitors Welcome Reception (In the Exhibit Hall)     Thursday, October 20, 2016 7:00 am — 3:20 pm Exhibit Hall Open 7:00 am — 8:00 am Breakfast in the Exhibit Hall 10:15 …
PowerPoint Presentation The Development of Hypophysitis in a Patient Treated with Pemprolizumab Ashley Draisey, DO and Kristen Westenfield, MD; Abbott Northwestern Hospital, Minneapolis, MN CASE PRESENTATION We report a case of a middle-aged male with merkel cell carcinoma receiving pembrolizumab, a PD-1 inhibitor, who presented to the emergency department with two weeks of …
media_CMS_CTPoct07
Hear how malnutrition affects people with cancer in different ways, even impacting cancer treatment plans.
While introducing its advocacy agenda for 2023, ACCC identified four core areas that will allow its members to continue delivering comprehensive, equitable cancer care.
NCOA ONCOLOGY DRUG NEWSLETTER FDA APPROVALS Flotufolastat F 18 injection (Posluma) The FDA has granted approval for the flotufolastat F 18 injection (Posluma; formerly 18F-rhPSMA-7.3) for PET of prostate-specific membrane antigen–positive lesions in patients with prostate cancer with suspected metastasis who are eligible for initial definitive therapy or in those with suspected recurrence …
TACOS ONCOLOGY DRUG NEWSLETTER FDA APPROVALS Flotufolastat F 18 injection (Posluma) The FDA has granted approval for the flotufolastat F 18 injection (Posluma; formerly 18F-rhPSMA-7.3) for PET of prostate-specific membrane antigen–positive lesions in patients with prostate cancer with suspected metastasis who are eligible for initial definitive therapy or in those with suspected recurrence …
Molecular-Testing-Lack-of-Pathology-Driven-Reflexive-Molecular-Testing
Health plans and pharmacy benefit managers should find ways to support treatment decisions made by cancer care providers and their patients rather than limiting where, how, and which drugs can be administered.
In this episode, our expert describes process improvement strategies to successfully integrate oral oncolytics into practice, and highlights how patient goals can be included in treatment planning.
TxSCO ONCOLOGY DRUG NEWSLETTER FDA APPROVALS Flotufolastat F 18 injection (Posluma) The FDA has granted approval for the flotufolastat F 18 injection (Posluma; formerly 18F-rhPSMA-7.3) for PET of prostate-specific membrane antigen–positive lesions in patients with prostate cancer with suspected metastasis who are eligible for initial definitive therapy or in those with suspected recurrence …
SCOS ONCOLOGY DRUG NEWSLETTER FDA APPROVALS Flotufolastat F 18 injection (Posluma) The FDA has granted approval for the flotufolastat F 18 injection (Posluma; formerly 18F-rhPSMA-7.3) for PET of prostate-specific membrane antigen–positive lesions in patients with prostate cancer with suspected metastasis who are eligible for initial definitive therapy or in those with suspected recurrence …
Learn more about sponsoring and exhibiting at the 2024 National Oncology Conference.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study Articles 2096 www.thelancet.com Vol 394 December 7, 2019 Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone …
Clinical Trials Highlights from ASCO's Annual Meeting Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=uacc20 Oncology Issues ISSN: 1046-3356 (Print) 2573-1777 (Online) Journal homepage: https://www.tandfonline.com/loi/uacc20 Clinical Trials Highlights from ASCO's Annual Meeting Walter Alexander To cite …
Accelerated Approvals Reconsidered On April 21, the FDA convened its Oncology Drug Advisory Committee (ODAC) to discuss the use of PI3K inhibitors for treating hematologic malignancies. The class of drugs under discussion target the phosphoinositide 3-kinase (PI3K) pathway, whose dysregulation has been implicated in assorted oncologic and autoimmune diseases. The meeting was occasioned by “concerning …
New Molecular Entities JaypircaTM (pirtobrutinib) – Loxo/Lilly Oncology received approval for its novel BTK inhibitor as treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy (including treatment with another BTK inhibitor). The approval was based on response rates observed among 120 MCL patients who were treated with …
Cancer Drugs are Expensive: Recent policy approaches and pitfalls Samyukta Mullangi, MD MBA Medical Director of Oncology at Thyme Care Medical Oncologist at Tennessee Oncology The annual cost of cancer care is expected to approach $246B by 2030. Source: https://www.fightcancer.org/sites/default /files/National%20Documents/Costs-of-Cancer-2020- 10222020.pdf Launch …
CCMED_3_2_Infographic_May_29_2020 Improving care for patients with stage III/IV NSCLC: learnings for multidisciplinary teams from the ACCC national quality survey Salgia et al. (2020) What are the barriers to effective MDT implementation and how can MDTs be optimized for NSCLC treatment? What Are the Barriers to Efficient Multidisciplinary Treatment of Stage III/IV Non-Small …